Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

1800-272-662
Shopping Cart 0
countryflagAU
Login

Home CompaniesKailera Therapeutics, Inc. Common Stock

Kailera Therapeutics, Inc. Common Stock

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
14.38 USD 0.00(0%)
Last update at 2026-11-11T21:00:00Z
VOLUME
609999
Market Cap
1743.71M

Momentum Score

…

Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera Therapeutics holds exclusive rights for global development and commercialization of four metabolic disease assets outside of Greater China, with therapies delivered through oral and injectable formulations. The company was founded in 2024 and is based in Waltham, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
14.00
Low
14.62
High
52 Week Price Range
13.32
Low
28.23
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
14.38
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
-0.03
ROE
-36.90%
Net Debt
-149.51M
ROCE
-24.52%
Diluted EPS TTM
-2.21

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31
Type yearly
Date 2025-12-31
Income before tax -148.96M
Net income -148.96M
Selling general administrative 49.23M
Reconciled depreciation 0.31M
Ebit -158.34M
Ebitda -158.03M
Depreciation and amortization 0.31M
Operating income -158.34M
Other operating expenses 158.34M
Interest income 11.05M
Net interest income 11.05M
Total revenue 0.00M
Total operating expenses 158.34M
Total other income expense net 9.38M
Net income from continuing ops -148.96M
Breakdown 2025-12-31 2024-12-31
Type yearly yearly
Date 2025-12-31 2024-12-31
Total assets 692.29M 178.44M
Other current assets 8.76M 0.34M
Total liab 1048.75M 397.22M
Total stockholder equity -356.46M -218.77M
Other current liab 37.84M 2.16M
Capital stock 0.00M 0.00M
Retained earnings -368.67M -219.71M
Cash 160.27M 175.18M
Total current liabilities 46.41M 6.91M
Net debt -149.51M -
Short term debt 1.04M -
Short long term debt total 10.75M -
Other stockholder equity 11.98M -
Total current assets 557.54M 177.61M
Long term investments 106.67M 0.00M
Short term investments 385.79M 0.00M
Net receivables 2.73M -
Accounts payable 7.53M 2.01M
Accumulated other comprehensive income 0.23M -
Non currrent assets other 15.67M 0.15M
Non current assets total 134.76M 0.83M
Capital lease obligations 10.75M 0.51M
Breakdown 2025-12-31
Type yearly
Date 2025-12-31
Investments -490.51M
Total cashflows from investing activities -492.60M
Net borrowings 100.00M
Total cash from financing activities 598.66M
Net income -148.96M
Change in cash -14.15M
Begin period cash flow 175.18M
End period cash flow 161.03M
Total cash from operating activities -120.21M
Issuance of capital stock 498.87M
Depreciation 0.31M
Other cashflows from financing activities -0.32M
Capital expenditures 2.09M
Change in working capital 16.78M
Stock based compensation 10.94M
Other non cash items 0.71M
Free cash flow -122.30M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
KLRA
Kailera Therapeutics, Inc. Common Stock		 -
-%		 14.38 - - - 1.59
NVO
Novo Nordisk A/S		 0.41
1.00%		 41.10 41.58 31.15 2.13 32.99
VRTX
Vertex Pharmaceuticals Inc		 -0.86
0.16%		 547.03 30.22 24.27 10.36 6.50
REGN
Regeneron Pharmaceuticals Inc		 43.35
4.73%		 959.41 29.07 20.12 7.57 3.82
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12

Profile*

Kailera Therapeutics, Inc. Common Stock

Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera Therapeutics holds exclusive rights for global development and commercialization of four metabolic disease assets outside of Greater China, with therapies delivered through oral and injectable formulations. The company was founded in 2024 and is based in Waltham, Massachusetts.

180 Third Avenue, Waltham, MA, United States, 02451

781 317 0290

https://www.kailera.com

145

Name Title Year Born
Mr. Ronald C. Renaud Jr., M.B.A. President, CEO & Director 1969
Mr. Paul Douglas Burgess J.D., M.S. Chief Operating & Business Officer 1974
Ms. Jamie Beth Coleman Chief Commercial Officer 1978
Mr. Douglas W. Pagan M.B.A. Chief Financial Officer 1972
Maura Gavaghan Vice President of Corporate Communications & Investor Relations NA
Mr. Scott M. Akamine J.D. Chief Legal Officer & Secretary 1985
Ms. Paula A. Cloghessy SHRM-SCP, SPHR Chief People Officer 1972
Dr. Scott M. Wasserman M.D. Chief Medical Officer 1970
Ms. Kathleen Tregoning M.A. Chief Corporate Affairs Officer 1971
Mr. Corey Manchester Treasurer NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CU6
AUD 2.05
+23.49%
DMP
AUD 25.06
+12.93%
G6M
AUD 2.74
+10.93%
XRO
AUD 75.17
+6.08%
SGR
AUD 0.17
+6.06%
AXQ
AUD 3.07
-18.35%
BOE
AUD 1.50
-9.39%
GQG
AUD 0.71
-8.97%
MI6
AUD 0.81
-8.52%
ELV
AUD 3.73
-8.35%

Equity Sectors*

  • Basic Materials

    -3.09%

  • Communication Services

    +0.75%

  • Consumer Cyclical

    +0.43%

  • Consumer Defensive

    +0.12%

  • Energy

    -1.07%

  • Financial Services

    -0.02%

  • Healthcare

    +1.08%

  • Industrials

    -0.22%

  • Real Estate

    +0.61%

  • Technology

    -1.69%

  • Utilities

    -0.18%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…